Sarumida joins the firm from Skadden Arps, where he served as a leader of its US-based Japan practice group.

 

Over 20 years of his practice in New York, Sarumida has represented a significant number of Japanese and multinational corporations in cross-border mergers and acquisitions, joint ventures, corporate finance transactions and other corporate matters.  He has also advised Japanese companies in various disputes in the areas of antitrust, product liability, intellectual property, and employment issues. 

 

He has recently represented Otsuka Pharmaceutical Co., Ltd. in its US$3.5 billion acquisition of Avanir Pharmaceuticals, Inc. and its $886 million acquisition of Astex Pharmaceuticals, Inc.

 

“There has been a dramatic surge in Japanese outbound investment, with companies having invested nearly $20 billion already this year. We are extremely excited to welcome Hiroshi to Orrick to assist our Japanese clients in executing strategic investments in the US and globally,” said King Milling, leader of Orrick’s global Corporate Business Unit.

 

“Having established Orrick’s Tokyo office as our first international office in 1997, the firm’s roots in Japan are extremely strong. We also have long approached our Japanese practice as a truly global practice, and we are honored to represent Japan’s leading companies in their investment activities, disputes and intellectual property matters throughout the world. We are therefore extremely excited to add an M&A partner of Hiroshi’s caliber to our global Japan Practice,” says Mark Weeks, leader of Orrick’s Tokyo office and co-leader of the firm’s Japan Practice.

 

Dual-educated in his native Japan and the United States, Sarumida holds an LLB from Kyoto University Faculty of Law, an MA in Legal Institutions from the University of Wisconsin, where he was a Rotary Scholar, and an LLM from the University of Wisconsin Law School, where he was a Graduate Research Fellow.  He is admitted to practice in New York.